Results of surgical and radiotherapy of prostatic cancer T1-4N0-1M0
- Авторлар: Matveev VB1, Tkachev SI1, Volkova MI1, Mitin AA1, Kalinin SA1, Shelepova VM1, Matveev VB1, Tkachev SI1, Volkova MI1, Mitin AA1, Kalinin SA1, Shelepova VM1
-
Мекемелер:
- Шығарылым: № 3 (2009)
- Беттер: 33-39
- Бөлім: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277390
- ID: 277390
Дәйексөз келтіру
Толық мәтін
Аннотация
Авторлар туралы
V Matveev
S Tkachev
M Volkova
A Mitin
S Kalinin
V Shelepova
V Matveev
S Tkachev
M Volkova
A Mitin
S Kalinin
V Shelepova
Әдебиет тізімі
- Kirby R. Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting. Nat. Clin. Pract. Urol. 2005; 2 (6): 298-303.
- Lepor H., Nieder A. M., Ferrandino M. N. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J. Urol. (Baltimore) 2001; 166 (5): 1729-1733.
- Heinzer H., Hammerer P., Graefen M. et al. Thromboembolic complication rate after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur. Urol. 1998; 33 (1): 86-90.
- Pepper R. J., Pati J., Kaisary A. V. The incidence and treatment of lymphoceles after radical retropubic prostatectomy. Br. J. Urol. Int. 2005; 95 (6): 772-775.
- Solberg A., Angelsen A., Bergan U. et al. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer. Scand. J. Urol. Nephrol. 2003; 37 (3): 218-221.
- Lerner S. E., Blute M., Zinke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J. Urol. (Baltimore) 1995; 154 (4): 1447-1452.
- Potosky A. L., Legler J., Albertsen J. et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J. Nat. Cancer Inst. 2000; 92 (19): 1582-1592.
- Madalinska J. B., Essink-Bot M.-L., de Koning H. J. et al. Quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J. Clin. Oncol. 2001; 19 (6): 1619-1628.
- Bianco F. J., Grignon D. J., Sakr W. A. et al. Radical prostatectomy with bladder neck preservation: impact of a positive margin. Eur. Urol. 2003; 43 (5): 461-466.
- Selli C., De Antoni P., Moro U. et al. Role of bladder neck preservation in urinary continence following radical retropubic prostatectomy. Scand. J. Urol. Nephrol. 2004; 38 (1): 32-37.
- Nandipati K. C., Raina R., Agarwal A. et al. Nerve-sparing surgery significantly affects long-term continence after radical prostatectomy. Urology 2007; 70 (6): 1127-1130.
- Wagner A. A., Link R. E., Trock B. J. et al. Comparison of open and laparoscopic radical prostatectomy outcomes from a surgeon's early experience. Urology 2007; 70 (4): 667-671.
- Kundu S. D., Roehl K. A., Eggener S. E. et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J. Urol. (Baltimore) 2004; 172 (6): 2227-2231.
- Kattan M. W., Wheeler Th. M., Scardino P. T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J. Clin. Oncol. 1999; 17 (5): 1499.
- Kattan M. W., Zelefsky M. J., Kuperlian P. A. et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J. Clin. Oncol. 2000; 18 (19): 3352-3359.
- Jeldres C. et al. Survival after radical prostatectomy and radiotherapy: A population-based study of 17,570 men. In: AUA. 2007. Abstr. 380.
- Gleave M. E., Goldenberg S. L., Chin J. L. et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J. Urol. (Baltimore) 2001; 166: 500-507.
- Schulman C. C., Debruyne F. M., Forster G. et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 2000; 38: 706-713.
- Alcantara P., Hanlon A., Buyyounouski M. et al. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 2007; 109 (1): 41-47.
- Zelefsky M. J., Fuks Z., Hunt M. et al. High-dose intensity-modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys. 2002; 53 (5): 1111-1116.